Get started

Duality Biotherapeutics, Inc. (China)

Alternate names: Duality Biologics, Duality Biologics (Shanghai) Co., Ltd., Duality Biologics (Suzhou) Co., Ltd., Duality Biotherapeutics, Duality Biotherapeutics, Inc., DualityBio Inc.
ROR: 01gh8xc13
OpenAlex ID: I4405267171
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models
2024 · Shengchao Lin, Yu Zhang, et al. · Journal of Translational Medicine · 32
PDF
Brain-wide alterations revealed by spatial transcriptomics and proteomics in COVID-19 infection
2024 · Ting Zhang, Yunfeng Li, et al. · Nature Aging · 23
PDF
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
2024 · Xi Li, Jun Yao, et al. · Journal of Translational Medicine · 20
PDF
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
2023 · Kathleen N. Moore, Dhanusha Sabanathan, et al. · Journal of Clinical Oncology · 19
An immunomodulatory antibody–drug conjugate targeting BDCA2 strongly suppresses plasmacytoid dendritic cell function and glucocorticoid responsive genes
2023 · Xi Li, Yu Zhang, et al. · Rheumatology · 19
PDF
Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate
2025 · Chenggang Li, Jun Yao, et al. · Clinical Cancer Research · 15
DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.
2025 · Aaron Lisberg, Shun Lu, et al. · Journal of Clinical Oncology · 12
PDF
57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors
2024 · Y. Cheng, L. Wu, et al. · Annals of Oncology · 12
PDF
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
2025 · Andrew Ohyama Parsonson, Chintan Gandhi, et al. · Journal of Clinical Oncology · 10
PDF
#430 DB-1303, a HER2-targeting ADC, for patients with advanced/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1/2a trial (NCT05150691)
2023 · Kathleen Moore, Vicky Makker, et al. · International Journal of Gynecological Cancer · 7
PDF
DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer
2025 · Xi Li, Liwen Liang, et al. · Cancer Biology and Medicine · 6
Abstract 2967: Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors
2023 · Chenggang Li, Jun Yao, et al. · Cancer Research · 5
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
2022 · Y. Zhang, B. Li, et al. · European Journal of Cancer · 5
PDF
DB-1305/BNT325, a novel trophoblast cell-surface antigen 2 antibody-drug conjugate, in patients with ovarian cancer: Efficacy and safety data from a phase I/II study
2025 · Maria Rubinstein, Bhavana Pothuri, et al. · Gynecologic Oncology · 4
Abstract 648: Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations
2025 · Erika P. Hamilton, Jianqing Zhu, et al. · Cancer Research · 4
689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
2023 · O. Marathe, Y. Cheng, et al. · Annals of Oncology · 4
PDF
Trastuzumab pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical phase 2 data
2026 · Bhavana Pothuri, Debra Richardson, et al. · Gynecologic Oncology · 3
Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models
2025 · Yunhua Zhou, Jun Yao, et al. · Cancer Research · 3
Abstract 1884: DB-1310, a novel Her3 targeting antibody-drug conjugate, exhibits therapeutic efficacy for solid tumors
2023 · Xi Li, Jun Yao, et al. · Cancer Research · 3
An exatecan derivative based linker-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD) risk
2022 · S. Lin, R. Shi, et al. · European Journal of Cancer · 3
IL1RAP Antibody–Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers
2026 · Hai-Feng Zhang, Edouard De Dreuzy, et al. · Cancer Discovery · 2
436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
2024 · J. O'Shaughnessy, J. Cortés, et al. · Annals of Oncology · 2
PDF
Abstract CT248: First in human trial of DB1305 in patients with advanced malignant solid tumors
2023 · Naoto T. Ueno, Jie Gao, et al. · Cancer Research · 2
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
2022 · S. Lin, Y. Zhang, et al. · European Journal of Cancer · 2
PDF
83RO Trastuzumab pamirtecan (T-Pam/DB-1303/BNT323) in patients (pts) with previously treated, HER2-expressing, advanced endometrial cancer (EC): Overall survival (OS) and efficacy in pt subgroups of a phase II dose-expansion cohort
2026 · K.N. Moore, X. Wu, et al. · ESMO Open · 1
PDF
Works count: 53
Citation count: 1,134
Year
Topic
Type